ABSTRACT NUMBER: ESOC2026A2297 USEFULNESS OF PHARMACOGENETIC DATA FOR PREDICTING VASCULAR OUTCOMES AND PHARMACODYNAMIC EFFICACY IN CLOPIDOGREL-TREATED ISCHEMIC STROKE PATIENTS
Jori Ruuskanen, Niina Kannisto, Lila Kallio, Päivi Helmiö, Juuso Blomster, Pauli Ylikotila, Aleksi Tornio, Johanna Schleutker · 2026
Read ABSTRACT NUMBER: ESOC2026A2297 USEFULNESS OF PHARMACOGENETIC DATA FOR PREDICTING VASCULAR OUTCOMES AND PHARMACODYNAMIC EFFICACY IN CLOPIDOGREL-TREATED ISCHEMIC STROKE PATIENTS by Jori Ruuskanen, Niina Kannisto, Lila Kallio, Päivi Helmiö, Juuso Blomster, Pauli Ylikotila, Aleksi Tornio, Johanna Schleutker (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13146303.txt.
Description
Jori Ruuskanen and co-authors report a 2026 conference study on whether gene profiles foretell events or drug response in patients taking a common clot drug after stroke. The drug needs a liver enzyme to switch on, and gene variants change how fast that happens. Guidance on gene testing for the drug stays unsettled.
Hospital records joined to a national gene pool covered more than three thousand treated patients with full follow-up. Clot events struck about three percent and bleeds under one percent within a year. Gene class showed no clear link to either event type. In a tested subgroup, platelet response leaned only weakly toward gene class. Over a third of the fastest gene group still failed to respond to the drug.
Catalog record
| CREATOR | Jori Ruuskanen, Niina Kannisto, Lila Kallio, Päivi Helmiö, Juuso Blomster, Pauli Ylikotila, Aleksi Tornio, Johanna Schleutker |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |